Sanofi Pasteur innovates in the Philippines. The pharmaceutical laboratory is launching there this Monday, April 4 a vast vaccination campaign against denguewith its product Dengvaxia®. This vaccine, which has been the subject of 20 years of research and required 1.5 billion euros of investment, will be administered to more than one million children in 6,000 public schools in the archipelago. This vaccination should “prevent eight out of 10 dengue-related hospitalizations, and up to 93% of severe dengue fever, including a rare but potentially fatal form called haemorrhagic dengue” highlighted Sanofi Pasteur in a press release. This dengue vaccine was approved for use in the Philippines on December 22, 2015 for people aged 9 to 45 years old for disease prevention.
70% of the worldwide weight of dengue fever in Asia
In addition to the Philippines, Dengvaxia® is also allowed in Brazil and at Mexico. But Asia remains the continent most concerned since “currently supports 70% of the worldwide weight of dengue“, according to Sanofi Pasteur.”In the Philippines alone, 200,000 cases of dengue were reported in 2013“specifies the laboratory. In addition, of the 10 endemic countries which participated in the clinical efficacy studies of Dengvaxia®, the Philippines showed the highest incidence of dengue cases.”The analysis also shows that in the Philippines, nearly 15% of febrile illnesses in children aged 9 and over are due to dengue.“Sanofi Pasteur alert.
This tropical infectious disease transmitted by the tiger mosquito Aedes albopictus manifests as high fever, headache, nausea, joint and muscle pain, and rash. In children and adolescents, severe dengue fever can pose a risk of death.
>> To read also:
Dengue fever: asymptomatic people participate in the transmission of the virus
Dengue fever: a mosquito plant to fight against transmission
First indigenous case of dengue fever discovered in France
Dengue fever: a transgenic mosquito authorized in Brazil
